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Systematic review to inform the development of a community pharmacy 1 
based intervention for people affected by dementia 2 
 3 
Abstract:  4 
Background: People living with dementia (PWD) frequently receive medicines regularly from their 5 
community pharmacy, thus providing an opportunity to address either directly or through a carer 6 
any unmet medicines-related needs. The aim of this systematic review was to identify and describe 7 
dementia-specific pharmacy-based interventions with potential for delivery through community 8 
pharmacy. This would inform the design of future services and associated trials. 9 
Methods: Ovid MEDLINE, EMBASE and CINAHL databases were searched along with, Opengrey, NHS 10 
evidence and references from included studies. Search terms included ‘dementia’ and ‘pharmacist’ 11 
plus their synonyms. Two independent researchers screened titles, abstracts and papers 12 
sequentially. A data extraction tool was developed based on PRISMA and EPOC, which included 13 
reporting all process, humanistic, clinical and economic outcome measures. The GRADE approach 14 
assessed the quality of the reviewed research. 15 
Results: The systematic review process identified twenty-nine studies. Interventions were 16 
categorised as medication review, targeted medicine intervention, education, memory screening 17 
and miscellaneous. Five studies were set in community pharmacy. Interventions frequently targeted 18 
antipsychotics, benzodiazepines and anticholinergic medication. Twenty interventions were 19 
medicine-related. Eighteen studies were categorised as ‘very low’ quality, often due to small sample 20 
size. 21 
Conclusions: The review identified a range of interventions, which could be delivered through 22 
community pharmacy, and potentially benefit PWD. Developing appropriate and efficient training 23 
and working in multi-disciplinary teams was identified as necessary for effectiveness. Further 24 
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research is needed to identify which service elements are likely to be acceptable to both patients 25 
and practitioners as well as the barriers and enablers to their implementation. 26 
 27 
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The number of people living with dementia (PWD) worldwide is expected to almost double every 20 32 
years and reach 131.5 million in 2050 1. In response to these predictions the World Health 33 
Organization has recently published a global action plan for 2017 – 2025 recommending the need to 34 
develop services which increase dementia awareness, improve dementia care support, provide 35 
support for carers and expand dementia related research 2. 36 
People living with dementia often have co-morbidities and will be prescribed several medicines in 37 
addition to those for dementia 3, 4. As the dementia progresses, the individual becomes less able and 38 
will increasingly need help from a paid or unpaid carer 5, 6. Carers can often lack medicine 39 
administration training, possess minimal knowledge about the medicines or understanding of how to 40 
communicate effectively with a person living with dementia. All of these factors could lead to sub-41 
optimal medicines management 7. The patient and/ or carer may often have a limited support 42 
network drawn from their families to their general practitioners, nurses or social workers 8. 43 
It is estimated that 89% of the United Kingdom (UK) population live within a 20 minute walk from a 44 
community pharmacy 9. Consequently, in many instances community pharmacists and their staff are 45 
ideally located to provide support to address unmet medicine-related needs for PWD either directly 46 
or through carers. The increasing use of technology such as dispensing robots 10 and pharmacy 47 
technicians reflects the fact that medicines supply has become a technical role. In addition to this, 48 
people are living longer and are staying within the community for longer periods of time, which is 49 
further increasing the need for accessible, high quality primary care. In response to this, pharmacists 50 
in the community setting must increasingly consider how they can utilise their medicines expertise 51 
to make a greater contribution to patient care. 52 
A significant evidence base built from a variety of countries (such as the UK, USA, Taiwan and 53 
Thailand) already exists for the management of a number of common chronic conditions such as 54 
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hypertension 11, 12, diabetes 13, 14 and services such as warfarin monitoring 15 through community 55 
pharmacy. The recent UK government review of evidence for clinical pharmacy services provided 56 
through community pharmacy recommended greater involvement in the management of long term 57 
conditions and that this could be delivered through a redesigned nationally funded adherence 58 
intervention (Medicines Use Review) 16.  59 
Similarly to hypertension and diabetes, dementia is another chronic disease, which may be 60 
potentially suitable for inclusion in such a service. However, the exact nature of the service and how 61 
best to deliver it is currently unknown.  62 
Systematic reviews focussed on healthcare interventions targeted at PWD which involve any 63 
healthcare professionals is sparse, particularly within a primary care setting. 64 
This systematic review therefore aims to identify and evaluate the current research of interventions 65 
aimed towards patients affected by dementia that utilise a member of the pharmacy team. This will 66 
be achieved by: (i) describing the study characteristics; (ii) describing the extent and nature of the 67 
interventions; (iii) identifying the effective and ineffective elements of the interventions and; (iv) 68 
assessing the quality of the studies. 69 
 70 
Methods 71 
Protocol registration 72 
The protocol for this systematic review was registered with PROSPERO on 12th July 2016: 73 
CRD42016042787 and the review was conducted between July and November 2016, 74 
Search Strategy and selection criteria 75 
Search Strategy 76 
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Search terms (defined in Supplementary data, appendix 1,) following the PICO (Population, 77 
Intervention, Comparator, Outcomes) method 17 aimed to retrieve studies where interventions 78 
utilising a pharmacy team member had occurred targeted at people affected by dementia. A 79 
previous scoping review by the author had revealed a dearth of studies in this field and therefore a 80 
broad research question with flexibility of the usual systematic review processes was required in 81 
order to extract the most information possible. This included the identification of any reported 82 
outcome measures (and the consequent inability to use PICOS search terms for ‘comparator’ and 83 
‘outcomes’), any types of study from any country, in any language and using no date restrictions. 84 
The sources searched in July 2016 were: 85 
 Ovid MEDLINE® In-Process & Other Non-Indexed Citations and Ovid MEDLINE® 1946 to 86 
present, OvidSP 87 
 EMBASE, 1974 to present, OvidSP 88 
 CINAHL Complete, EBSCOhost 89 
 Grey literature at www.opengrey.eu 90 
 NHS Evidence with the search restricted to ‘Primary research’, ‘Drug/medicine 91 
management’ and ‘Policy and service development’ for types of information and ‘Public 92 
health’, ‘social care’, ‘clinical’ and ‘drugs and technologies’ for area of interest. 93 
 Bibliographies of included studies 94 
Retrieved studies were initially screened for their suitability by two independent researchers using 95 
just their titles. Successful titles then had their abstracts screened against the inclusion criteria by 96 
two independent researchers. Full articles were then retrieved and assessed for their inclusion by 97 
two independent researchers. Discrepancies were resolved through discussion between the 98 
researchers and a Cohens Kappa Coefficient was calculated at each stage as a measure of inter-rater 99 
agreement. 100 
Inclusion Criteria 101 
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Selected studies were assessed against the following inclusion criteria: (i) minimum of 70% 102 
prevalence of dementia within the target population. Following the scoping review by the author, 103 
the prevalence was reduced to 70% so that a higher number of studies could be included which may 104 
provide helpful insights into potential interventions that could be of use in PWD within a community 105 
pharmacy setting ; (ii) a pharmacy team member had a key role in delivering the intervention 106 
meaning that the intervention would not have been able to be conducted without the input of the 107 
pharmacy team member; (iii) empirical data available (i.e. not the published protocol) and; (iv) the 108 
presence of an intervention. 109 
Exclusion Criteria 110 
Studies were excluded if there was no intervention present, no member of a pharmacy team present 111 
for any aspect of the intervention, or the target population for the intervention was not mostly 112 
dementia. Studies could be excluded for more than one reason. 113 
 114 
Data extraction 115 
An extraction tool was specially designed for this review and was based on the Preferred Reporting 116 
Items for Systematic Reviews and Meta-Analyses (PRISMA)18 and the Cochrane Effective Practice and 117 
Organisation of Care (EPOC) Review Group Data Collection Checklist 19. Data recorded included: 118 
study characteristics; nature and extent of intervention; outcome data measures and results; 119 
effective and ineffective elements of interventions. The effective and ineffective elements were 120 
obtained from the authors’ own reflections within the paper and then categorised. 121 
Once data extraction was completed, a sample of the extracted data was checked for accuracy by a 122 




Due to the broad nature of this review, meta-analyses, which would usually be applied to systematic 125 
reviews and is featured within PRISMA, was not feasible. 126 
Quality assessment 127 
The overall quality of the studies was assessed using an adapted version of the GRADE Working 128 
Group (Grades of Recommendation, Assessment, Development and Evaluation Working Group) as 129 
suggested by Cochrane17. GRADE places an initial quality rating on each study based on their study 130 
design (randomised controlled trials (RCTs) are given a rating of HIGH and non-RCTs are rated LOW). 131 
Quality ratings can then be upgraded or downgraded to ‘VERY HIGH’, ‘HIGH’, ‘MODERATE’ ‘LOW’ or 132 
‘VERY LOW’ based on 8 criteria.  The previous scoping review had suggested most current studies 133 
were likely to be small service evaluations. This meant that the GRADE upgrade criteria (large 134 
magnitude of effect, dose response and the effect of all plausible confounding factors would be to 135 
reduce the effect) were not likely to be relevant in most cases. It was therefore decided to use the 136 
downgrading factors listed below as the criteria for both upgrades and downgrades of studies20:  137 
 Reporting bias (such as unreported results for stated outcome measures), 138 
 Inconsistency (such as inconsistency of results or unexplained heterogeneity), 139 
 Indirectness (such as the inclusion of people outside of interest or small number of 140 
comparators),  141 
 Imprecision (such as small sample size or wide confidence intervals), 142 
 Limitations in design (such as a high number of limitations or high likelihood of bias in the 143 
study design).  144 
 145 
Results 146 
Twenty-nine studies were selected for data extraction and the PRISMA flowchart for data selection is 147 
presented in Figure 1.  148 
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Study Characteristics 149 
Table 1 presents the study characteristics of the 29 included studies. Only one study was a 150 
randomised controlled trial, whereas 21 were service evaluations. Seven studies were only available 151 
as conference abstracts and 1 article was written in French (which was translated using online 152 
translation software). Settings included clinics, nursing homes, and hospitals, with 5 studies set in 153 
community pharmacies. The majority of studies were conducted after 2010 and were mostly 154 
conducted in the USA or the UK.  155 
 156 
Extent and nature of Interventions 157 
The identified interventions were grouped into five categories as follows: medication review, 158 
targeted medicine intervention, education, memory screening, or miscellaneous. 159 
 160 
Scope of interventions 161 
Twenty interventions (69%) were medication related (Table 2) with the use of antipsychotics (n=10), 162 
anticholinergics (n=6) and/or benzodiazepines (n=6) in people affected by dementia being a key 163 
theme. Education interventions included a Donepezil outpatient service providing advice and 164 
support to patients newly prescribed Donepezil 21 and the training of Primary Care Navigators who 165 
can provide advice, support and signposting services in primary care to people affected by dementia 166 
22. Memory screenings conducted by pharmacists utilised well-known screening techniques such as 167 
the Mini-cog 23, 24; Mini-Mental Screening examination (MMSE) and the Clock-Drawing test 25. The 168 
studies in the miscellaneous category included an audit identifying an array of interventions within 169 
community pharmacy 26 and the assessment of patient’s cognitive function and ability to fill and use 170 




Multidisciplinary involvement  173 
Only 5 (17%) of the studies were conducted solely by a pharmacist with no input from other 174 
healthcare professionals. Table 2 also summarises the input of other healthcare professionals 175 
(HCPs), which were required in additional to pharmacists, for the successful implementation of the 176 
interventions. The most common professional to be included were doctors who held a variety of 177 
roles from general practitioners that followed up with patients after a referral from a community 178 
pharmacist 24 to a geriatrician, who was part of weekly multidisciplinary medication reviews in care 179 
home residents 28. 180 
 181 
Reported outcomes 182 
A wide variety of outcome measures were identified within this review with most being ‘humanistic’ 183 
or ‘process’ related in nature and fewer being ‘clinical’. Table 4 shows examples of some of these 184 
outcomes reported with examples from the studies. Although only 1 study specified an economic 185 
related outcome measure ‘patient’s willingness to pay for memory screening service’, 3 studies in 186 
total reported economic based results. 187 
Effective and Ineffective elements 188 
Effective elements 189 
A range of elements were reported as being effective, the most common being related to the use of 190 
a pharmacist in the intervention and the use of multidisciplinary teams. Watanabe et al 21 states how 191 
the value of involving pharmacists in dementia care and their outpatient model could also apply to 192 
local dispensing pharmacies for providing support to patient’s families. Collier et al 28 noted how 193 
regular multidisciplinary medicine review meetings had a positive impact on prescribing 194 
psychotropics and reducing the number of elderly residents’ medications . Other elements found 195 
effective included minimal training 23, 25, mixed methods training 22, low cost of intervention 29, the 196 
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intervention being quick to conduct 23, 25, accessibility of intervention 22, 23 and the ability for the 197 
intervention to be replicated 24. 198 
Ineffective elements 199 
Fourteen elements were recorded by authors, as ineffective (with 5 derived from one article 22). 200 
Ineffective elements included: reliance on a dementia register for identifying patients with dementia 201 
using antipsychotics 30, poor level of follow-ups from doctors following pharmacist 202 
recommendations and communication difficulties between HCPs 24, service-user involvement being 203 
dependant on self-reporting and poor tool sensitivity 25, difficulties raising awareness of the 204 
intervention, having the time to conduct the intervention and convincing doctors of potential 205 
benefits of the intervention 22. 206 
 207 
Quality 208 
One study received a quality rating of ‘high’ due to its’ randomised control design whereas 26 209 
studies were rated ‘low’ or lower (see Table 5) quality study designs which largely consisted of 210 
service evaluations. Fourteen studies were downgraded for imprecision which was largely due to the 211 
small sample sizes reported and only 5 studies were upgraded.  212 
 213 
Discussion 214 
This review provides evidence that pharmacy teams have provided services in a range of settings but 215 
few which incorporate community pharmacies. In addition to this, a large proportion of the studies 216 
included in this review were service evaluations, which leads to there being insufficient high-quality 217 
evidence to supporting the development of future community pharmacy interventions. 218 
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The most common countries to have conducted the research were the UK and the USA and the most 219 
common forms of intervention involved a medicines review or the provision of support to either a 220 
PWD or their carer. A large number of the interventions targeted specific medicine groups such as 221 
antipsychotics, benzodiazepines and anticholinergics and the majority of interventions involved 222 
working with other HCPs. Doctors and nurses were predominantly involved but some studies utilised 223 
the expertise of other HCPs such as social workers, physiotherapists and other allied HCPs. These 224 
multidisciplinary teams were reported by some authors as contributing effectively to their studies 225 
along with training methods, accessibility, and the ability for the model to be replicated in other 226 
settings. 227 
Few ineffective elements were reported and no common themes were found but key elements to 228 
consider included difficulties identifying potential service users and the lack of time to perform the 229 
new role. 230 
A large strength to this review was that the author initially conducted a scoping review, which 231 
enabled the inclusion criteria to be broadened and the search terms to be refined which ensured 232 
that all relevant studies were included. 233 
Several of the included studies were only presented as conference abstracts and so limited 234 
information for data extraction was available which was a limitation to this review. A further 235 
limitation was that detailed information regarding the education of staff members was not recorded 236 
or critiqued, which in hindsight would have been a valuable element to evaluate. 237 
The Kappa scores calculated at each stage of this review ranged from ‘fair’ to ‘moderate’ 31 which 238 
shows that some disagreement was present between the reviewers. However, the discussions, 239 
which followed ensured that the disagreements were resolved, and that no reviewer bias could 240 
impact the final list of included studies or jeopardise the quality of the results. 241 
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The small number of community pharmacy-based interventions found in this review may follow 242 
from the difficulties with including PWD in research. Identifying, recruiting and gaining informed 243 
consent can be barriers that researchers may find difficult when designing large scale studies with 244 
this group 32. Studies have previously reported that community pharmacy staff are motivated to take 245 
part in research so as to help improve the profession and use as an opportunity to learn 33. However, 246 
a lack of time (for either recruiting patients into a study or for conducting the intervention itself), 247 
staff, money, knowledge, skills and difficulties communicating between both the study teams and 248 
the pharmacy staff members have been described as common barriers for community pharmacy 249 
staff to take part in research studies 33-35. These factors need to be carefully considered in the 250 
development of an intervention to ensure successful involvement of community pharmacies in large 251 
scale trials. Additionally, focussing on these factors will assist the intervention to be implemented 252 
into community pharmacies effectively and ensure that the service reaches its maximum potential 253 
for level of activity and patient benefit. 254 
The UK and the United States have a history of being within the top 10 of having the largest 255 
pharmaceutical market value in the world, with the latter repeatedly being at number 1 36. This may 256 
provide some reasoning for why these countries feature so heavily within this review’s results. The 257 
inclusion of other countries such as Sweden, Slovenia and Norway shows how research is slowly 258 
building momentum worldwide which is being further driven by such events such as the World 259 
Health Organisation (WHO) recognising dementia as a public health priority in 2012 8 and the World 260 
Health Assembly adopting the Global Action Plan on Dementia in 2017 2.  261 
Pharmacies already provide certain medication review services, which are readily available in 262 
community pharmacies in the UK and are not targeted towards particular patients. The medication 263 
reviews reported within this review concentrated on certain medicines, which are more specific to 264 
PWD. Antipsychotics are commonly prescribed in dementia to help relieve Behavioural and 265 
Psychological Symptoms of Dementia (BPSD) but can increase the risk of cerebrovascular adverse 266 
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events or death and should therefore be prescribed only where necessary and should be reviewed 267 
regularly 37, 38. Benzodiazepines are commonly prescribed in the elderly 39 yet 1 in 7 will have an 268 
adverse event such as dizziness or confusion 40. Anticholinergics further reduce the amount of 269 
cholinesterase in the body and therefore counteract the effects of the acetylcholinesterase 270 
inhibitors used to manage dementia and a patient’s confusion can be enhanced increasing the risk of 271 
falls, fractures and hospitalisation 41. These medicines are often prescribed inappropriately 4, 42 in 272 
PWD and therefore an obvious role for community pharmacists could be to incorporate a criteria 273 
such as the anticholinergic burden scale or the drug burden index 43 into their medication reviews. In 274 
order to undertake this however, the pharmacist will need to receive appropriate training and have 275 
access to up to date national and local guidelines regarding the use of such medicines. 276 
With the wide range of interventions identified, it is understandable that there was also a wide 277 
range of outcome measures reported amongst the studies. Although the results tended to be in 278 
favour of the interventions, the lack of economical data provides a barrier for potential long-term or 279 
nationwide implementation. Future studies evaluating the use of community interventions should 280 
endeavour to include an economical element in order to assess whether the intervention is not only 281 
effective but also cost-effective. 282 
The elements reported as effective by authors provides guidance on what components are 283 
important in the development of a future intervention. A community pharmacy intervention for 284 
people affected by dementia should ideally have an effective staff training model which builds on 285 
existing skills, be low-cost, relatively quick to implement. It should also provide evidence-based 286 
benefit to the patient and / or family, be easily replicated in other settings and be accessible to all 287 
service-users. 288 
Another effective element reported was the incorporation of other HCPs. The need for pharmacists 289 
in all settings to work in less isolation for the successful implementation of future interventions is 290 
clearly highlighted in this review by the high number of studies that utilised other HCP’s. 291 
14 
 
Multidisciplinary teams can lead to positive changes in health care such as improvements in patient 292 
care and reduced hospital stays 44 and this review shows how PWD may interact with a large range 293 
of professionals throughout their dementia journey ranging from doctors, nurses and pharmacists to 294 
music therapists, occupational therapists and social workers.  295 
Community pharmacists currently work in professional isolation on a regular basis and this may 296 
represent a significant barrier to intervention development. When designing a future intervention, 297 
relevant healthcare and non-healthcare professionals should be involved in the design and 298 
encouraged to identify how their involvement could improve patient care. Early and continuous 299 
involvement of other HCPs may improve the success of the intervention and would be in line with 300 
the recommendations made within the Murray Review 16 for further community pharmacy 301 
integration. 302 
High quality study designs (such as randomised controlled trials) have previously been used to test 303 
the effectiveness of community pharmacy based services for other chronic conditions such as 304 
diabetes 13 and hypertension 11, yet this review highlighted how there have been only a small 305 
number (and of low quality), studies in the field of dementia. This may reflect the relatively recent 306 
shift in focus to increase public awareness of dementia and improve dementia care.  307 
Action area 7 of the WHOs Global Action Plan is ‘dementia research and innovation’ which aims to 308 
double the global research on dementia between 2017 and 2025 45. This review supports comments 309 
within the Global Action Plan regarding the current dearth of high quality research being undertaken 310 
in this area and emphasises the need for larger, higher quality study designs to be conducted such as 311 
randomised controlled trials. Higher quality studies in this area will generate higher quality evidence 312 
and will enable developed interventions for people affected by dementia to be implemented more 313 
effectively. An increase in high quality studies will also have implications for policy makers who will 314 
be more driven to develop evidence-based guidance and policies within this area, which will further 315 





This review highlights a large range of interventions targeted at people affected by dementia, which 319 
incorporate a member of the pharmacy team and offering potential for a larger role for community 320 
pharmacy in the care of people affected by dementia. For the role to continue to evolve and to 321 
provide enhanced support to patients, community pharmacists will need appropriate training and to 322 
be further integrated into primary care teams. Before such services can be developed and tested it 323 
will still be necessary to identify which elements identified within this review are believed to be and 324 
evidenced to be acceptable, feasible and effective if delivered through a community pharmacy. It is 325 
also important to identify the barriers and enablers to their implementation and suitable approaches 326 
to service design, which either utilise or address them. Better quality studies testing the 327 
effectiveness of new services are then needed in order to provide more influential evidence for 328 
service commissioners. 329 
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    Japan Clinic 35  
Patel 52 2010     USA Clinic 20  
Sakakibara 
53 
2014    b Japan Clinic 50  






































Child 30 2011     UK GP Surgery 70  
Stuhec 57 2013     Slovenia GP Surgery 629  
Efjestad 58 2011     Norway Hospital (all) 50  












































a Randomised controlled trial; b Non-randomised intervention study; c Audit 
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Collier 28 Ap        
Conlon 46 Ap        
D’Souza 63 Ch        
Farrell 59         
Fountain 55         
Frausto 60        b 
Furniss 29 Ap, Be        
Gustafsson 56 Ap, Ch, Be        
Kröger 48         
Mouchoux 61 Ap, Ch, Be       c 
Paquin 62 Ap, Ch, Be        
Patel 52 Ch        
Stuhec 57         
Targeted Medicine Intervention 
Cations 64 Ap       d 
Child 30 Ap        
Efjestad 58 Ch        
Hursh 47 Ap        
Maidment 49 Ap, Be        
Nakamura 51 Donepezil        




   e    
Monette 50        




       
Rickles 24        
Setter 54        




      f 
Manrai 26    g    
a  Ap = Antipsychotic, Ch = Anticholinergic, Be = Benzodiazepine); b Other members of inpatient medical team; c 
Physiotherapist, occupational therapist, music therapist, speech therapist; d Care home staff; e Community pharmacy 






Table 3. Descriptions of included interventions 509 
Study Intervention Study time 
period 
Anderson 27 





Primary Care navigators (PCNs) trained by variety of methods including training days, e-
learning and ongoing mentoring. PCN role then piloted which included interventions 
such as non-clinical 'bridging; role connecting and signposting those with dementia and 
carers to services, support and information. 
June 2014 – 
Feb 2015 
Breslow 25 
Following 8 hours of home study, a 6-hour live program and a 4-hour refresher course, 
memory screening was conducted 2 pharmacists using MMSE, category (animal) 
fluency test and clock-drawing test. Results sent to GP. Satisfaction survey completed. 
Pharmacies received $75 remuneration for each participant screened. 
Unknown 
Cations 64 Pharmacist and GP proposed antipsychotic dose reductions when used for BPSD. 12 months 
Child 30 
People on a dementia register, receiving low-dose antipsychotics identified and 
included in a pharmacist-led medication review aimed at reducing antipsychotic use. 
Jan-Dec 2011 
Collier 28 
Regular multidisciplinary medication review meetings on the prescribing of 
psychotropic medications (follow-up study to Conlon et al.) 
Sept 2013 
Conlon 46 
Regular multidisciplinary medication review meetings on the prescribing of 
psychotropic medications. 
March 2009 – 
March 2010 
D’Souza 63 
Telephone and home visits by social worker and nurse, pharmacist conducts 
medication review and reviews with nurse.  Support from interdisciplinary team which 
meets weekly to formulate plans and interventions. 
2 years 
Efjestad 58 
Anticholinergic drug scale (ADS) score created for each patient and suggestions 
provided to geriatricians for changes to medicines. 
June – Dec 
2011 
Farrell 59 
45-minute patient interview, review of charts and medicines communication with 




Medication review and home visit (involving MMSE examination) to patient. Several 
changes made with help of interdisciplinary team. 
Days 
Frausto 60 
Inpatient face to face meeting for medicine reconciliation and recommendations to 
inpatient team. Once discharged, another medicine reconciliation by phone with 
recommendations made to primary care provider. 
May 2013 – 
Oct 2014 
Furniss 29 
Pharmacist assessed whether use of neuroleptics complied with US OBRA a guidelines 




Medication review to assess for specific potentially inappropriate drugs. Suggestions 




Interdisciplinary team aimed at reducing antipsychotic use by: Staff education, using 
non-pharmacological measures and improving documentation tools to track behaviour 
interventions and pain management. 
May – Aug 
2008 
Kröger 48 
Following 180 mins of education sessions, pharmacist performed medication reviews 
using a tailored list created to aid medicine optimisation. Recommendations discussed 
with nurses and physicians. 




All medication (with an emphasis on psychotropics) of residents with dementia within a 
nursing home reviewed based on National Prescribing Centre level 3 medication review 
criteria and US OBRA (Ombudsman reconciliations) guidelines. Problems defined, 




Interventions identified included: dose alterations, delivery date information to 
patients, medication reconciliation and medication counselling.  
6 weeks 
Monette 50 
Following an interdisciplinary educational program (which included overviews on non-
pharmacological approaches for disruptive behaviours and the need to administer the 
lowest effective dose),  pharmacists identified patients on a monthly basis taking 
antipsychotics at the same dosage for more than 3 months and requested the physician 
to assess if the drug could be reduced or discontinued. 




Analysis of medicines on admission to the unit and multidisciplinary reviews. 




Pharmacist recommended Donepezil dose increase from 5mg/day to 10mg/day to 
physician if patient assessed to be at AD stage 5 or 6 with use of a checklist, 
questionnaire and swallowing test. 
4 months 
  510 
23 
 
Table 3 (continued). Descriptions of included interventions 511 
Study Intervention Study time 
period 
Paquin 62 
Comprehensive review of medications, a medication safety check via use of a checklist 
and a telephone call with patients and caregivers 2-5 days post discharge. 
2010 – 2012 
Patel 52 
Interprofessional clinic for patients with cognitive impairment that included a clinical 
pharmacist who assessed their medication charts for pharmacotherapeutic problems. 
July – Sept 
2010 
Rickles 24 
Memory screening assessment (mini-cog and animal fluency test) by trained 
pharmacist followed by customized counselling and referral to GP if needed. 




A pharmacist proposed the reduction of prescribed benzodiazepines. March – July 
2014 
Setter 54 
Rapid 3-minute mini-cog (which included a three-item recall task and a clock-drawing 
task) to homebound patients to screen for undiagnosed cognitive impairment. 
Sept 2004 – 
June 2005 
Sonnett 23 
Patients were administered the mini-cog and primary care providers contacted if 
results required action.  
June 2006 – 
March 2007 
Stuhec 57 





Donepezil Outpatient Consultation Service provided the patient and carer’s with 
detailed information about Donepezil and AD. 
April 2008 – 
March 2012 
 512 
  513 
24 
 
Table 4. Examples of ECHO outcome measures and results reported 514 
ECHO 
category 
Study Outcome measure Result reported 
Economical Rickles 24 Willingness to pay 56.4% were ‘willing to pay’ for the service 
Clinical 
Nakamura 51 Dementia severity 
20/27 patients showed at least one stage 
improvement in severity 
Efjestad 58 
Anticholinergic drug scale 
scores (ADS) 
Where ADS was ≥, median score reduced 
from 2.5 to 1 (p=0.009) post intervention 
Humanistic 
Furniss 29 Number of falls and deaths 
Fewer deaths (4 vs 14) in intervention homes 
(p=0.028) 
Fountain 55 Risk of falls Risk of fall reduced 
Nakamura 51 
Caregiver burden (J-ZBI_8* 
score)  
Mean J-ZBI_8* score for personal strain 
reduced from week 0 to week 4 (p<0.05) 
through to week 16 (p<0.01). 
Rickles 24 Patient satisfaction 




Number of prescribed 
medicines per patient 
Reduction in average number of medicines 
per patient from 7.1 to 6 (p<0.003) 
Mouchoux 61 Number of interventions 
190 interventions proposed by pharmacist 
with 77.9% accepted 
Monette 50 
Proportion of discontinued 
psychotropics 
40 (49.4%) psychotropics discontinued 
Rickles 24 
Proportion of patients 
referred 
54 (33.5%) of screened patients referred 
* Japanese version of the Zarit Caregiver Burden Interview 
  515 
25 
 






































































0 0 0 - - VERY LOW* 
Conlon 46 0 0 0 0 - VERY LOW 
D’Souza 63 0 0 - 0 0 LOW 
Farrell 59 0 0 0 - 0 VERY LOW* 
Fountain 55 0 0 0 - - VERY LOW* 
Frausto 60 0 0 - 0 0 VERY LOW* 
Furniss 29 0 0 0 0 0 HIGH 
Gustafsson 56 0 0 0 + 0 MODERATE 
Kröger 48 0 0 - - - VERY LOW* 
Mouchoux 61 0 0 0 0 0 LOW 
Paquin 62 - 0 0 0 0 VERY LOW 
Patel 52 0 0 0 - - VERY LOW 





- - 0 - 0 VERY LOW* 
Child 30 - + 0 0 0 LOW 
Efjestad 58 0 0 0 - 0 VERY LOW 
Hursh 47 - 0 0 - 0 VERY LOW* 
Maidment 49 0 0 0 - - VERY LOW* 
Nakamura 51 0 0 - 0 0 VERY LOW 
Sakakibara 53 - 0 0 - 0 VERY LOW 
Anonymous 22 
Education 
0 0 0 - + LOW 
Monette 50 0 0 0 + 0 MODERATE 




- 0 0 - 0 VERY LOW* 
Rickles 24 - 0 0 0 0 VERY LOW 
Setter 54 0 0 0 - 0 VERY LOW 
Sonnett 23 0 0 0 0 0 LOW 
Anderson 27 
Miscellaneous 
0 0 - 0 0  VERY LOW 
Manrai 26 0 0 0 0 0    LOW 
Key: Initial score downgraded= - ; Initial score stays the same= 0; Initial score upgraded= + 
*Final score technically lower than given score as ‘VERY LOW’ is the lowest score GRADE uses  
